Vanguard Group
TTRX

Vanguard Group’s Turn Therapeutics TTRX Stock Holding History

Vanguard Group’s Portfolio TTRX Stock Details TTRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$119K Buy
+30,156
New +$126K ﹤0.01% 4155

Other funds holding TTRX

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WSC
Wellington Shields & Co New York $392M AUM 30.65% 1-Year Est. Return
DI
DDFG Inc Thousand Oaks, California $464M AUM 16.56% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
BBHC
Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
RW
RVW Wealth Los Angeles, California $1.52B AUM 23.06% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group's TTRX Position: Q4 2025 in Review

Vanguard Group opened a new position in Turn Therapeutics (TTRX) in Q4 2025: 30,156 shares worth $119K. The stake represents ﹤0.01% of the portfolio and ranks #4155 among its holdings.

22 funds tracked by Wall St. Rank hold TTRX as of Q4 2025.

  • Vanguard Group held 30,156 shares of Turn Therapeutics worth $119K as of Q4 2025.
  • Turn Therapeutics was a new Vanguard Group position in Q4 2025.
  • Turn Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #4155 holding.
  • 22 funds tracked by Wall St. Rank held Turn Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.